Please wait while the formulary information is being retrieved.
TZIELD (teplizumab-mzwv)
- delay onset of stage 3 type 1 diabetes mellitus
1 mg/mL intravenous solution
- Infuse 1,030 mcg/m2 over at least 30 minute(s) by intravenous route once daily on days 5 through 14 of treatment
Default screening record
- Infuse 65 mcg/m2 over at least 30 minute(s) by intravenous route onceon day 1 of treatment
- Infuse 125 mcg/m2 over at least 30 minute(s) by intravenous route once on day 2 of treatment
- Infuse 250 mcg/m2 over at least 30 minute(s) by intravenous route once on day 3 of treatment
- Infuse 500 mcg/m2 over at least 30 minute(s) by intravenous route once on day 4 of treatment
- Infuse 1,030 mcg/m2 over at least 30 minute(s) by intravenous route once daily on days 5 through 14 of treatment
- natalizumab
- Tysabri
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Pregnancy
Contraindicated
- Abnormal hepatic function tests
- Anemia
- Lymphopenia
- Neutropenic disorder
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- None
TZIELD (teplizumab-mzwv)
- delay onset of stage 3 type 1 diabetes mellitus
- Leukopenia
- Lymphopenia
- Headache disorder
- Skin rash
More Frequent
Severe
Less Severe
- Anemia
- Increased alanine transaminase
- Infection
- Neutropenic disorder
- Thrombocytopenic disorder
- Cytokine release syndrome
- Diarrhea
- Nausea
- Pharyngitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Serum sickness
Less Severe
- Urticaria
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
teplizumab-mzwv
Safety and effectiveness not established in pediatric patients age < 8 years.
- 1 Day – 8 Years
- Safety and effectiveness not established in pediatric patients age < 8 years.
Teplizumab-mzwv
- Severity Level:
1
- Additional Notes: Insufficient human data available; mfr does not recommend during pregnancy
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Teplizumab-mzwv
Manuf states may discard breastmilk during and for 20 days after treatment
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Manuf states may discard breastmilk during and for 20 days after treatment |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Delay onset of stage 3 type 1 diabetes mellitus | |
| E10.9 | Type 1 diabetes mellitus without complications |
| 0-9 | A-Z |
|---|---|
| E10.9 | Type 1 diabetes mellitus without complications |
Formulary Reference Tool